Researchers have repurposed the receptor that pulls vitamin B12 from food, using it as a drug ferry to sneak a nitric oxide payload across the blood brain barrier into one of the deadliest brain cancers. The data are still in rats.
A vitamin that the body already pulls out of food to build red blood cells is being repurposed as a drug ferry, engineered to slip past the brain's protective filter and unload a nitric-oxide payload directly into glioblastoma tumors in rats. The work, published June 27 in Oncoscience, describes a modified form of vitamin B12 called nitrosylcobalamin that crossed the blood-brain barrier in animals and concentrated inside tumor tissue while leaving healthy brain largely untouched.
The mechanism matters because glioblastoma remains one of the deadliest cancers in the central nervous system. Even with surgery, radiation, and the standard chemotherapy temozolomide, median survival sits between roughly 12 and 15 months. The blood-brain barrier, the dense web of tightly packed cells that lines the brain's blood vessels, blocks most drugs from ever reaching a tumor in meaningful concentrations. Researchers have been trying for decades to find a clean way across.
Nitrosylcobalamin's approach is to piggyback on biology the body already runs. Cells naturally grab vitamin B12 from the bloodstream through a specific receptor called the transcobalamin receptor, which is overexpressed on many fast-dividing cells, including glioblastoma. The modified molecule, according to the Oncoscience paper, carries a nitric-oxide group attached to the cobalt core of B12. Once inside the tumor, it appears to release nitric oxide slowly, which can interfere with cancer cell survival and sensitize cells to other therapies.
In the reported animal studies, nitrosylcobalamin did more than accumulate. It showed synergy with two distinct partners: temozolomide, the current standard-of-care alkylating chemotherapy for glioblastoma, and TRAIL, a signaling molecule that triggers cancer cells to self-destruct through apoptosis. The journal's press release flags these combinations as the central mechanistic finding of the paper.
A broader survey of cancer cell lines adds both promise and a caveat. The compound was tested against the NCI-60 panel, a National Cancer Institute collection of 60 human tumor cell lines used to screen experimental drugs. The paper's pharmacokinetic and tissue-distribution results describe glioblastoma targeting in animal models, and ScienceDaily's coverage flags a related nuance: CNS-origin lines in the NCI-60 panel showed only moderate sensitivity on average. That nuance is easy to lose in headline summaries that lump all brain cancers together.
The lead author on the paper is Joseph A. Bauer, listed with affiliations at both Nitric Oxide Services LLC and the Cleveland Clinic Foundation's Taussig Cancer Center. The dual academic-commercial byline is a relevant detail for readers tracking who controls the compound's development path. News-Medical's coverage outlines the same mechanism story without the dual-affiliation wrinkle, and EurekAlert's release reproduces the journal's framing.
What this work is not is a cure, a breakthrough, or a confirmed drug candidate ready for human testing. Every efficacy claim in the published paper rests on pharmacokinetic studies, tissue-distribution measurements, and animal-model tumor experiments. There is no clinical trial data, no human safety profile, and no established dosing for patients. Glioblastoma has a long, well-documented record of preclinical results that looked striking in rodents and then collapsed in early-phase human trials. That history is also why the word "promising" in the press coverage should be read as a marker of stage, not a guarantee of outcome.
What to watch next is whether the team or a partner moves toward IND-enabling toxicology, the kind of pharmacology and safety work that precedes a Phase 1 trial. If nitrosylcobalamin can clear those preclinical hurdles, the real question becomes whether its nitric-oxide cargo adds enough over standard temozolomide to justify the extra manufacturing complexity a B12 analog demands. Right now the answer lives in rat tissue. The human version, if it ever arrives, is still several years and several regulatory gates away.